Eiko Lifesciences Q2 Profit Climbs to Rs 1.56 Crore

Revenue from operations reached Rs 17.72 crore for the quarter ended September 30, 2026.
Net profit after tax stood at Rs 1.56 crore for the same period.

Reader Takeaway: Steady financial growth paired with a new renewable energy venture provides a potential long-term revenue diversification path.

What just happened

Eiko Lifesciences has released its financial results for the quarter and half-year ended September 30, 2026. Alongside the financial update, the company confirmed the formation of a 50-50 joint venture named 'Oval Eiko Resources Private Limited'. This new entity will be formed through Eiko's wholly-owned subsidiary, Eiko Scientific Solutions LLP, in partnership with Oval Projects Engineering Limited. The company has already received name approval from the Ministry of Corporate Affairs for this venture.

Why this matters

The move into the renewable energy sector represents a strategic pivot for the company. By entering the Compressed Bio Gas (CBG) production and distribution market, Eiko intends to diversify its business model, which is currently centered on chemicals and logistics. The initial investment for this 50% stake in the JV is modest at Rs 2.50 lakh, signaling a measured entry into the green energy space.

The backstory

The company has demonstrated consistent quarter-on-quarter and year-on-year growth. Revenue has increased to Rs 17.72 crore in the September 2026 quarter compared to Rs 11.67 crore in the same quarter last year. Profit margins have also shown resilience, rising from Rs 1.28 crore to Rs 1.56 crore over the same timeframe.

Risks to watch

Investors should monitor the execution risks associated with entering a new, capital-intensive sector like renewable energy. Diversification away from the core chemicals business requires successful integration and scaling of the new joint venture's operations. Any delays in the CBG project rollout could impact planned revenue streams.

What to track next

Watch for updates on the operational launch of Oval Eiko Resources and the deployment of capital for its CBG plants. Additionally, monitor if the core specialty chemicals business maintains its growth trajectory in the coming quarters.